FDA approves Mirum’s LIVMARLI for cholestatic pruritus

2024-03-14

上市批准孤儿药临床结果临床3期并购

FDA approves Mirum’s LIVMARLI for cholestatic pruritus

Preview

来源: Pharmaceutical Technology

Mirum Pharmaceuticals’s LIVMARLI (maralixibat) oral solution is now available in the US for cholestatic pruritus in patients with PFIC. Credit: Mirum Pharmaceuticals / Business Wire.

The US Food and Drug Administration (FDA) has approved Mirum Pharmaceuticals’s LIVMARLI (maralixibat) oral solution to treat cholestatic pruritus.

The medication is intended for patients aged five years and above with progressive familial intrahepatic cholestasis (PFIC).

A once-daily, orally administered ileal bile acid transporter inhibitor, LIVMARLI is the sole FDA-approved treatment for PFIC.

The approval is based on findings from the Phase III MARCH clinical trial in 93 PFIC patients.

The randomised trial enrolled people with PFIC genetic types PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6, along with people with unidentified mutational status.

See Also:

Terns scores FDA orphan designation for CML therapy

Preview

来源: Pharmaceutical Technology

FDA issues CRL to Mapi Pharma for GA Depot to treat RMS

Preview

来源: Pharmaceutical Technology

The FDA, the European Commission and Health Canada have also granted approval for LIVMARLI for the treatment of cholestatic pruritus in patients with Alagille syndrome Alagille syndrome in their respective regions.

In addition to its current approvals, Mirum has filed a supplemental new drug application to the FDA. The aim is to introduce a higher concentration formulation of LIVMARLI, which was utilised in the Phase III MARCH study.

This could expand the treatment’s label for younger PFIC patients later in 2024.

A rare genetic disorder, PFIC results in progressive liver disease that can go on to cause liver failure.

Mirum Pharmaceuticals CEO Chris Peetz stated: “LIVMARLI has the potential to have a transformational impact for patients with cholestatic pruritus associated with PFIC, and importantly, offers an option for those patients with the rarest of subtypes.

“Thank you to the patients, families and clinicians whose study participation made this approval possible.”

In September 2023, the company concluded the acquisition of the bile acid product portfolio of Travere Therapeutics.